Panagora Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Panagora Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-62,968	Closed	-$574K	–	1460
2022 Q1	$574K	Sell	62,968 -72,121	-53%	-$751K	﹤0.01%	1162
2021 Q4	$2.02M	Buy	135,089 +104,825	+346%	+$1.85M	0.01%	642
2021 Q3	$778K	Hold	30,264	–	–	﹤0.01%	1086
2021 Q2	$789K	Buy	+30,264	New	+$863K	﹤0.01%	1120

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Panagora Asset Management's ALLO Position: Q2 2022 in Review

Panagora Asset Management sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 62,968 shares — an estimated $574K sold.

Panagora Asset Management first reported a position in ALLO in Q2 2021 and held it in 4 quarters. The position peaked at $2.02M in Q4 2021. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

Panagora Asset Management reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
Panagora Asset Management sold 62,968 Allogene Therapeutics shares in Q2 2022, an estimated $574K.
Panagora Asset Management first reported a position in Allogene Therapeutics in Q2 2021 and held it in 4 quarters.
Panagora Asset Management's Allogene Therapeutics position peaked at $2.02M in Q4 2021.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Panagora Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.